Grants for Nonprofits
384 open opportunities. Open federal grant opportunities that nonprofit organizations are eligible to apply for — each with a plain-English summary of who qualifies, the deadline, and the award size.
NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)
Due Oct 15, 2027National Institutes of Health · Amount varies
This NIH/NIDCD R21 early-career award supports basic and clinical research by scientists beginning an independent research career in NIDCD mission areas such as hearing, balance, smell, taste, voice, speech, or language. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible. It cannot fund thesis or dissertation research, and is intended to generate preliminary data for a later R01. No award amount is specified.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreEarly Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
Due Oct 15, 2027National Institutes of Health · Amount varies
This NIH/NIMH award (R61/R33) funds early-stage testing of pharmacologic or device-based interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Studies must follow NIMH's experimental-therapeutics design, so the scope is specific.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreFirst in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)
Due Oct 15, 2027National Institutes of Health · Amount varies
This NIH/NIMH U01 cooperative agreement funds first-in-human and early-stage clinical trials of novel investigational drugs or neuromodulatory devices for psychiatric disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations rather than individuals. No award amount is specified. It emphasizes academia-industry partnerships, so the scope is narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreDevelopment of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
Due Oct 15, 2027National Institutes of Health · Amount varies
This NIH/NIMH award (R61/R33) funds development and testing of novel psychosocial therapeutic and preventive interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Work must follow NIMH's experimental-therapeutics approach, so the scope is specific.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreEarly Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
Due Oct 15, 2027National Institutes of Health · Amount varies
This NIH/NIMH R33 grant funds early-stage testing of pharmacologic or device-based interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is aimed at research organizations rather than individuals. No award amount is specified. The study must follow NIMH's experimental-therapeutics design requirements, so the scope is narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreDevelopment of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
Due Oct 15, 2027National Institutes of Health · Amount varies
This NIH/NIMH R33 grant funds pilot research developing and testing novel psychosocial therapeutic and preventive interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is geared toward research organizations rather than individuals. The award amount is not specified in the listing. Applicants must use the experimental-therapeutics approach described, so the research focus is narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreNEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
Due Oct 16, 2027National Institutes of Health · Amount varies
This NIH/NEI R21 funds vision-related research projects based on secondary analysis of existing datasets, including related statistical methodology development; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. The focus is limited to vision-related secondary data analysis.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreNIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)
Due Oct 18, 2027National Institutes of Health · Amount varies
This NIH/NIDCD U01 cooperative agreement funds clinical trials for the treatment or prevention of communication disorders, specifically trials requiring FDA oversight, intended to establish efficacy, or carrying higher risk. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. Foreign organizations are not eligible. No award amount is specified, and the trial focus makes the scope narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreInnovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Due Oct 20, 2027National Institutes of Health · Amount varies
This NIH/NINDS award (R61/R33) funds pharmacology and in vivo efficacy studies to advance candidate therapeutics for neurological and neuromuscular disorders toward further translational development. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations rather than individuals. No award amount is specified. The work is narrowly defined preclinical drug-development research.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreInnovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
Due Oct 20, 2027National Institutes of Health · Up to $750K
This NIH/NINDS award (R61/R33) funds development of in vitro and ex vivo assays and screening to identify candidate therapeutics for neurological and neuromuscular disorders; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $750,000. The early-stage drug-discovery focus makes the scope narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 moreInnovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
Due Oct 20, 2027National Institutes of Health · Up to $750K
This NIH/NINDS award (R61/R33) funds development and validation of animal models and tissue systems that mimic neurological and neuromuscular disorders to support future neurotherapeutic discovery; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $750,000. The model-development focus makes the scope narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 moreNational Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
Due Oct 25, 2027National Institutes of Health · Amount varies
This NIH/NIMH U01 funds individual research projects to discover and develop new drugs and neurostimulation approaches for mental disorders, substance use disorders, and alcohol use disorder. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations rather than individuals. No award amount is specified. The drug/device discovery focus makes the scope narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreCancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
Due Oct 25, 2027National Institutes of Health · Amount varies
This NIH/NCI R34 planning grant funds the design and preparation of cancer prevention and control clinical trials, covering screening, early detection, supportive care, and survivorship. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations, not individuals. No award amount is specified. It funds trial-planning activities rather than the trials themselves.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreNational Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
Due Oct 25, 2027National Institutes of Health · Amount varies
This NIH/NIMH U19 funds multi-project programs to discover and develop new drugs and neurostimulation approaches for mental disorders, substance use disorders, and alcohol use disorder. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations, not individuals. No award amount is specified. It supports large multidisciplinary programs, so the scope is narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreCancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
Due Oct 25, 2027National Institutes of Health · Amount varies
This NIH/NCI U34 planning grant funds the design and preparation of cancer prevention and control clinical trials, including studies on screening, early detection, and survivorship. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it is aimed at research organizations, not individuals. No award amount is specified. It funds trial-planning work rather than the trials themselves, so review the scope carefully.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 morePriority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
Due Nov 5, 2027National Institutes of Health · Amount varies
This NIH/NIDDK R01 funds HIV/AIDS research aligned with NIDDK's mission and the NIH Office of AIDS Research priorities. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Projects must fit the stated HIV/AIDS research priorities, so the scope is specific.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreLimited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)
Due Nov 5, 2027National Institutes of Health · Amount varies
This NIH/NINDS U01 is a limited competition open only to applicants holding existing NINDS-supported clinical trial cooperative agreement awards that need more time and resources to finish. Because it is restricted to current grantees, new applicants are not eligible; foreign organizations are also excluded. No award amount is specified. This opportunity does not apply to organizations that do not already hold the relevant NINDS award.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreAlzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Due Nov 5, 2027National Institutes of Health · Up to $1.5M
This NIH/NIA U01 funds preclinical and early (Phase I) clinical development of new drug candidates that aim to prevent, slow, or treat Alzheimer's disease. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $1.5 million. Basic mechanism studies, repurposed drugs, and stand-alone clinical trials are out of scope, so the research focus is narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 moreBRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)
Due Nov 8, 2027National Institutes of Health · Amount varies
This NIH BRAIN Initiative R01 funds development of computational theories, models, and methods for analyzing complex brain-circuit data, to be shared with the research community. Eligible applicants are research organizations, including faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets institutions rather than individuals. No award amount is specified. The work is narrowly scoped to neural-circuit tool building, so confirm fit before applying.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreNIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
Due Nov 12, 2027National Institutes of Health · Up to $350K
This NIH/NIDA award funds research education programs that train clinicians and clinical researchers in substance use and substance use disorder research. Eligible applicants are research and education institutions, including HBCUs, Hispanic-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is aimed at organizations, not individuals. Awards run up to about $350,000. Note the program supports research education only, not non-research clinical training, so review the stated scope carefully.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 more